These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Topiramate slow dose titration: improved efficacy and tolerability. Albsoul-Younes AM; Salem HA; Ajlouni SF; Al-Safi SA Pediatr Neurol; 2004 Nov; 31(5):349-52. PubMed ID: 15519117 [TBL] [Abstract][Full Text] [Related]
25. [Psychosis following treatment with topiramate]. Voskuil PH Ned Tijdschr Geneeskd; 2003 Feb; 147(7):319-20; author reply 320. PubMed ID: 12622013 [No Abstract] [Full Text] [Related]
26. Psychotic symptoms in methamphetamine psychotic in-patients. Srisurapanont M; Ali R; Marsden J; Sunga A; Wada K; Monteiro M Int J Neuropsychopharmacol; 2003 Dec; 6(4):347-52. PubMed ID: 14604449 [TBL] [Abstract][Full Text] [Related]
27. Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. Mula M; Trimble MR; Sander JW Epilepsia; 2007 Dec; 48(12):2322-6. PubMed ID: 17711462 [TBL] [Abstract][Full Text] [Related]
28. Hypohidrosis and hyperthermia during topiramate treatment in children. Incecik F; Hergüner MO; Altunbaşak S Turk J Pediatr; 2012; 54(5):515-8. PubMed ID: 23427516 [TBL] [Abstract][Full Text] [Related]
29. The importance of being seizure free: topiramate and psychopathology in epilepsy. Mula M; Trimble MR Epilepsy Behav; 2003 Aug; 4(4):430-4. PubMed ID: 12899865 [TBL] [Abstract][Full Text] [Related]
33. Increased frequency of psychosis after second-generation antiepileptic drug administration in adults with focal epilepsy. Adachi N; Fenwick P; Akanuma N; Hara K; Ishii R; Okazaki M; Ito M; Sekimoto M; Kato M; Onuma T Epilepsy Behav; 2019 Aug; 97():138-143. PubMed ID: 31252268 [TBL] [Abstract][Full Text] [Related]
34. A pilot study of Topiramate (Topamax) in the treatment of tonic-clonic seizures of alcohol withdrawal syndromes. Rustembegovic A; Sofic E; Kroyer G Med Arh; 2002; 56(4):211-2. PubMed ID: 12518536 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J; Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356 [TBL] [Abstract][Full Text] [Related]
36. Oligohydrosis and hyperthermia: pilot study of a novel topiramate adverse effect. Ben-Zeev B; Watemberg N; Augarten A; Brand N; Yahav Y; Efrati O; Topper L; Blatt I J Child Neurol; 2003 Apr; 18(4):254-7. PubMed ID: 12760427 [TBL] [Abstract][Full Text] [Related]
37. Othello syndrome in patients with Parkinson's disease. Georgiev D; Danieli A; Ocepek L; Novak D; Zupancic-Kriznar N; Trost M; Pirtosek Z Psychiatr Danub; 2010 Mar; 22(1):94-8. PubMed ID: 20305599 [TBL] [Abstract][Full Text] [Related]
39. Hypohidrosis during topiramate treatment: a rare and reversible side effect. Cerminara C; Seri S; Bombardieri R; Pinci M; Curatolo P Pediatr Neurol; 2006 May; 34(5):392-4. PubMed ID: 16648001 [TBL] [Abstract][Full Text] [Related]
40. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Arroyo S; Dodson WE; Privitera MD; Glauser TA; Naritoku DK; Dlugos DJ; Wang S; Schwabe SK; Twyman RE; Acta Neurol Scand; 2005 Oct; 112(4):214-22. PubMed ID: 16146489 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]